Avadel Pharmaceuticals plc Stock News

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate des

DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript

FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate desi

Avadel's flagship compound, FT218, is on its way towards approval with the FDA. FT218 once nightly dose has been proven more efficient and better accepted by patients than competing products.

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for

Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year b

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate des

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

DUBLIN, Ireland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate des

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Harmony Biosciences intends to raise $100 million in an IPO. The firm is developing and commercializing treatments for narcolepsy and related conditions.